Dr. Reddy’s Molflu will be priced at Rs. 35 per capsule with 10 capsules contained per strip, and the total course of 40 capsules over 5 da...

The recommended dose of molnupiravir is 800 mg twice a day for five days. With companies planning to launch 200 mg capsules, a patient will...

Shares of Strides Pharma were up 2.3 per cent while those of Cipla gained 1.4 per cent. Dr Reddy’s scrip registered a gain of close to a pe...

Union health minister Mansukh Mandaviya said 13 companies in India will manufacture the drug approved for restricted use under emergency si...

Molnupiravir is the first COVID-19 drug authorised by the Drugs Controller General of India (DCGI) for the treatment of COVID-19 infection ...

The drug firm said it is able to manufacture the active pharmaceutical ingredient (API) as well as the formulation for Molnupiravir, and ha...

Under the licensing deal, Hetero will be allowed to expand access of Molnupiravir in India and in other low-and middle-income countries, fo...

"This launch is yet another step in our endeavour to enable access to all treatments in COVID care. We continue to be guided by the power o...

Drug maker Cipla said it will soon make molnupiravir capsules available at all leading pharmacies and Covid treatment centers across the co...

Union Health Minister Mansukh Mandaviya on Tuesday said that the Central Drug Authority CDSCO has approved the Serum Institute of India's C...

The recommendations have been sent to the Drug Controller General of India (DCGI), which will soon decide on their approval, people in the ...

The SEC on COVID-19 of the CDSCO, which reviewed the emergency use authorisation (EUA) applications of Serum Institute of India (SII) for t...

The company said it has received its clinical trial approval on May 19, 2021, from the Drug Controller General of India (DCGI) to perform a...

The Hyderabad-based firm said the first dose under the phase-III trials was given to a patient in the city-based Yashoda Hospitals.

Natco Pharma on Friday said it has initiated phase-III clinical trials of Molnupiravir capsules to evaluate its efficacy in treating patien...

Molnupiravir was originally developed to treat influenza before US-based Merck initiated research to repurpose drug for use against SARS-Co...

The development comes close on the heels of findings announced by the researchers that Molnupiravir was found effective for treating the pa...